We partner to deliver innovative medicines that transform patients’ lives.
We have established an excellent track record of in-licensing and out-licensing deals with our global and regional partners.
Global Strategic Partnership with AbbVie
Focusing on Certain New CD47 Antibodies in Development
Future milestone payments up to $1.295B + Royalties*
I-Mab will continue to prioritize lemzoparlimab in China with the potential to be first-to-market.
* I-Mab will be eligible to receive, and AbbVie will pay, up to US$1.295 billion in the development, regulatory and sales milestone payments, and the tiered royalties at rates from mid-to-high single digit percentages on global net sales outside of Greater China for certain new anti-CD47 antibodies currently in development, or the original milestone payments and tiered royalties previously disclosed in I-Mab’s Form 20-F for the fiscal year 2021 for other licensed products.
Commercial Partnership with Jumpcan
Focusing on Commercializing Eftansomatropin Alfa in China
Total aggregate value under the agreement $315M + Royalties / Shared Profits*
This deal brings together the strengths of I-Mab’s leadership in innovation and Jumpcan’s leadership in pediatric medicine in China to accelerate the commercialization of eftansomatropin alfa.
* Jumpcan pays US$35 million upfront and US$280 miilion upon development, registration, and sales milestone achievements. Sharing profits on a 50/50 basis, I-Mab is entitled to receive tiered low double-digit royalties on net sales of product.
Partner with Us
We are currently seeking strategic partners in the following areas
- In-licensing highly differentiated oncology assets
- Co-development and co-commercialization of our innovative products for the global market